Co-Authors
This is a "connection" page, showing publications co-authored by Fevzi Altuntas and Tugçe Yigenoglu.
Connection Strength
4.914
-
Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. Transfus Apher Sci. 2021 Dec; 60(6):103237.
Score: 0.962
-
The outcome ofancy. COVID-19 in patients with hematological malign J Med Virol. 2021 03; 93(3):1255.
Score: 0.911
-
Convalescent plasma therapy in patients with COVID-19. J Clin Apher. 2020 Aug; 35(4):367-373.
Score: 0.891
-
Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption. Transfus Apher Sci. 2020 Aug; 59(4):102855.
Score: 0.889
-
Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2021 02; 60(1):103017.
Score: 0.229
-
COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2021 04; 56(4):952-955.
Score: 0.228
-
Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2021 Feb; 60(1):102955.
Score: 0.226
-
The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021 02; 93(2):1099-1104.
Score: 0.225
-
Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting. Balkan Med J. 2017 Apr 05; 34(2):132-139.
Score: 0.178
-
COVID-19 clinical course and blood groups: Turkish population-based study Turk J Med Sci. 2021 08 30; 51(4):1659-1664.
Score: 0.060
-
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med. 2022 01; 17(1):135-139.
Score: 0.059
-
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020 Oct; 26(7):1676-1682.
Score: 0.056